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Abstract
Background: Infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) can lead to
chronic liver disease and hepato-cellular carcinoma (HCC). This cross-sectional study estimated
the prevalence and identified risk factors associated with Hepatitis B surface antigen (HBsAg) and
HCV antibody (anti-HCV) sero-positivity among children 1 to 15 years of age.
Methods: The study targeted the low to middle socioeconomic population that comprises 80% to
85% of the population. Consent was obtained from parents of the eligible children before
administering questionnaire and collected a blood sample for anti-HCV and HBsAg serology.
Results: 3533 children were screened for HBsAg and anti-HCV. 1826 (52 %) were males. 65 (1.8
%) were positive for HBsAg, male to female ratio 38:27; mean age 10 ± 4 years. 55 (1.6 %) were
positive for anti-HCV with a mean age 9 ± 4 years. 3 (0.11%) boys were positive for both HBsAg
and anti-HCV. The overall infection rate was 3.3 % in the studied population. Hepatitis BsAg was
more prevalent in subjects who received therapeutic injections 45 (69.2%) positive [Odd Ratio OR
= 2.2; 95% Confidence interval CI: 1.3–3.6] inspite of using new needle and syringe 44 (67.7%)
positive [OR = 2.2; 95% CI: 1.3–3.7] and vaccination in the government healthcare facilities 46 (70.7
%) positive with [OR = 3.0; 95% CI: 1.4–6.4]. These factors were not significant in anti-HCV
positive cases.
Conclusion: There is a need to educate general population regarding HBV and HCV infection and
risks associated with inappropriate therapeutic injections. Hepatitis B vaccine should be
administered to all newborns regardless of maternal HBsAg status.
Background
Viral hepatitis is a major public health problem in all parts
of the world. Pakistan is in the intermediate HBV preva-
lence area with a carrier rate of 3–4% [1]. Chronic hepati-
tis B is a severe problem in Pakistan [2,3]. In a community
based study 31% percent had hepatitis B core antibodies
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study the frequency of HBsAg in healthy subjects was
2.9% and HBs Ab 35% [5]. Horizontal transmission, par-
ticularly in early childhood, accounts for most cases of
chronic HBV infection in intermediate prevalence areas
like Pakistan [6]. Children may acquire HBV infection
through horizontal transmission via minor breaks in the
skin or mucous membranes or close bodily contacts with
other children. Zuberi et al. described HBsAg prevalence
of 2.5% in pregnant women and out of these 17% HBeAg
and 61% anti HBe positive [7]. Low frequency of HBsAg
and HBeAg in pregnant women makes vertical transmis-
sion a less important cause of transmission [8].
The burden of HCV related chronic liver disease (CLD) in
Pakistan has increased. Earlier studies showed that of all
patients presenting with CLD, 16.6% were anti-HCV pos-
itive [9] more recent data shows nearly 60–70% patients
with CLD tend to be positive for anti-HCV [2,10,11]. It
has been demonstrated that nearly 50% patients with
hepatocellular carcinoma (HCC) in Pakistan are anti-
HCV positive [12]. Blood transfusions is still the major
cause of HCV transmission in the country; as a survey of
blood banks in the large urban centers of the country
showed that only about 25% of them tested blood and
blood product donations for HCV infection to keep the
cost down. [13]. A number of studies have shown the rela-
tionship between therapeutic injections using non-sterile
needles and the transmission of HCV [14]. There is an
enormous dependence on parenteral therapy for treat-
ment, both in the form of injections and infusion of drips,
driven by cultural beliefs in the power of parenteral ther-
apy. Additional risk factors that may be important modes
of transmission include are excessive use of barbers for
shaving [15], ear piercing and non-sterile surgical and
dental practices of unqualified health care workers
(quacks).
The mean age of developing CLD in developing countries
including Pakistan is much lower as compared to devel-
oped countries, suggesting that individuals are being
infected at a younger age in this part of the world. In 1994,
a cross sectional study done in children revealed 3% were
HBsAg positive [16]. The sero-prevalence of HCV in chil-
dren appears to be low in Pakistan, with 0.2% and 0.4%
children infected under the age of 12 and between 12–19
years respectively [16]. The aim of this study was to esti-
mate the prevalence of anti-HCV and HBsAg to screen for
current infection and also to identify the risk factors asso-
ciated with anti-HCV and HBsAg sero-positivity among
children (1 to 15 years of age) in Karachi, Pakistan.
Methods
Study design and setting
The study was carried out in May, 2003- August, 2004 and
targeted the low to middle socioeconomic population of
Karachi which constitute about 80% to 85% of the popu-
lation. Also, this group is less educated and more exposed
to some of the important established risk factors for the
diseases under study. All children 1 to 15 years of age liv-
ing in the study were eligible to participate in the survey.
A prospective cross-sectional study was conducted to
achieve the primary objective to estimate the prevalence
of anti-HCV and HBsAg sero-positivity and evaluate
potential risk factors by comparing seropositive and
seronegative for HBsAg and anti-HCV antibody among
children 1 to 15 years of age. A two-stage cluster sampling
technique was employed to draw the required sample.
The Federal Bureau of Statistics (FBS) divided the city into
5000 clusters each of about 250 households. On average
each household contained 7 individuals of which about
40% (3 individuals per household) were aged 1 to 15
years. About 85% (4250) of the total 5000 clusters were in
the lower and middle-income group (average household
income less than Rupees 7440/month). The survey was
conducted in ten geographically separate clusters. Sam-
pling unit was a household selected from within each
cluster through random sampling. We randomly selected
about 338 children from each sampled cluster that con-
tained about 700 children 1 to 15 years of age.
Data collection and serology
Trained community health workers (CHW) reached the
selected household and approached the head of the fam-
ily. They explained the purpose and objectives of the study
and asked for written informed consent from parents of
the eligible children before administering the question-
naire and collecting a blood sample. The trained CHW
administered a pre-tested questionnaire to the mother/
father of each child to obtain information on socio-
demography and potential risk factors for HCV and HBV
transmission after taking written informed consent. The
questions in the questionnaire gathered following infor-
mation in addition to demographic characteristics includ-
ing age, gender, socio-economic status, educational level
in years, number of injections in past six months to ten
years, type of health care provider for injections. History
of surgical procedure, especially circumcision in male
children, blood or blood products transfusion in child,
factors predisposing to horizontal transmission of Hepa-
titis B, history or current use of intravenous drugs in the
child, siblings or in other family members; history of tat-
tooing or ear piercing in child; jaundice or diagnosis of
HCV or HBV among siblings, parents or other family
members living in the same house. The collected samples
were centrifuged within 6 hours of collection and after
serum separation stored at -70°C. Serology for anti-HCVPage 2 of 10
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after the completion of data collection. Third generation
enzyme linked immunosorbent assay (ELISA) visual test
kits for anti-HCV and HBsAg (by International Immuno
Diagnostics CA, USA) were used to detect the presence of
anti-HCV and HBsAg in the sera of the study subjects.
Data management and analysis plan
EPI Info version 6 was used for data entry [17]. The data
was analyzed using Statistical Package for Social Sciences
(SPSS) version 10.0 [18]. The analysis was carried out at
three levels descriptive analysis, univariate and multivari-
ate analysis. Descriptive statistics of socio-demographic
variables and other characteristics of the sampled popula-
tion were computed. Means and standard deviations (SD)
were calculated for quantitative variables and proportions
for categorical variables. Univariable logistic regression
analysis was performed to measure association of out-
come with each independent variable. Odds ratios (OR)
and 95% confidence intervals (CI) was calculated for each
association. Associations among independent variables
were assessed using appropriate tests before performing
multivariate analysis. Multiple logistic regression models
were used to examine the association between the inde-
pendent variables and the main outcome variables, Hep-
atitis B and C virus, while controlling for the effects of
other covariates. P value < 0.05 was considered as statisti-
cal significant.
Using software EPI Info [17] and assuming 4% prevalence
of anti-HCV in the study population with 95% confidence
level and a bound on error of +1 % the estimated sample
size was 1475. Sample size required for the ratio of chil-
dren with HCV and children without HCV of 1: 6, to
detect an odds ratio of 3.0 at 95% confidence level and
power of 80%, for the prevalence of risk factor estimated
to be 6% was 1617 children using the EPI Info software
[17]. Sample size calculated for the risk factor was larger
than the one for estimation of prevalence of HCV. There-
fore, a sample of 1617 children was targeted and this sam-
ple size covered the primary and the secondary objectives.
For cluster sampling we incorporated the design effect. We
calculated a design effect of 1.9 [19]. The sample size
required after multiplying with design effect is: n = 1617
× D = 1617 × 1.9 = 3073. However, this sample size was
inflated by 10%, to account for non-responders, making
the final target sample size of 3380 children.
Ethical issues
Informed written consent was obtained from the parent of
the study subject. The serological results were provided to
the parents at the completion and kept strictly confiden-
tial. The parents of infected children were provided with
appropriate information on the prevention of further
spread of these infections and referred to the nearest gov-
ernment medical facility for guidance.
Results
All the parents were interviewed and a total of 3533 chil-
dren were screened for HBsAg and anti-HCV. The age
range was 1–15 years. 1826 (52%) were males and 1707
(48%) were females. The over all infection rate was 3.3 in
the studied population. 65 (1.8%) was positive for HBsAg
with male to female ratio of 38:27 (Table 1). Those posi-
tive for HBsAg had a mean age of 10 ± 4 years. 55 (1.6%)
was positive for anti-HCV with a mean age of 9 ± 4 years.
32 (58%) were boys and 23 (42%) were girls (Table 2). 3
(0.11%) was positive for both HBsAg and anti-HCV and
they were all males.
Demographic features of the study population
Area of study population
The distribution of study population was 1328 (37.6%) in
the north, 443 (12.5%) west, 439 (12.4 %) east, 878
(24.9%) south and 445 (12.6%) central area of the city.
In reference to other areas i.e. 18 (1.4%) north and 3
(0.7%) west of the city where overall HBsAg prevalence
was 21 (2.1%), the prevalence of HBsAg in the east was 24
(5.5%) [OR = 4.8; CI: 2.7–8.7 p < 0.001] and in south 18
(2.1 %) [OR = 1.8; CI: 0.3–3.3 p = 0.08]. The distribution
of anti-HCV positive cases was 8 (1.8%) in the east, 11
(2.5%) central, 16 (1.8 %) south, 17 (1.3%) and west 3
(0.7%). However, anti-HCV distribution was not statisti-
cally significant among different areas of the city.
Accommodation
The living quarters of the studied population both HBsAg
and anti-HCV positive and negative had a mean of 2
rooms (range of 1–7 rooms). It was being shared among
7 individual household members.
Educational status
The educational status of the parents showed that when
mothers were uneducated it was significantly associated
with positive HBsAg status on Univariable analysis (Table
1) however, it was not on multivariable analysis (Table 3).
Educational status of the parents was not significantly
associated with anti-HCV positive (Table 2).
Ethnic origin
The ethnic distribution of various groups in the study
population is shown in Table 1, 2. 19 (29.2 %) of the chil-
dren positive for HBsAg were ethnic mohajirs, 10 (15.4
%) punjabi, 4 (6.2 %) pathan, 12 (18.5 %) balochi, 1
(1.5%) sindhi while 19 (29.2%) belonged to other ethnic
groups. 23 (41.8 %) mohajirs, 16 (29 %) punjabi, 4 (7.3
%) pathan, 3 (5.5 %) balochi, 1 (1.8 %) sindhi and others
8 (14.6 %) were positive for anti-HCV. HBsAg and anti-Page 3 of 10
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Hepatitis B virus
Risk Factor Positive n (%) Negative n (%) Odds Ratio (OR) 95% confidence 
interval (CI)
P value
Therapeutic Injections
Yes 45 (69.2) 1766 (50.9)
No 20 (30.8) 1702 (49.1) 2.2 (1.3 – 3.6) 0.003
Use of new needle & and syringe
Yes 44 (67.7) 1694 (48.8)
No 21 (32.3) 1774 (51.2) 2.2 (1.3 – 3.7) 0.003
No: of Injections in the last year
<2 injections 4 (12.5) 371 (28.2) Reference
2–5 injections 13 (40.7) 462 (35.2) 2.6 (0.8 – 8.1)
>5 injections 15 (46.8) 481 (36.6) 2.9 (1.0 – 852) 0.140
Received Blood Transfusion
Yes 1 (1.5) 51 (1.5)
No 64 (98.5) 3417 (98.5) 1.0 (0.1 – 7.7) 0.964
Hospitalized
Yes 16 (24.6) 590 (17)
No 49 (75.4) 2878(83) 1.6 (0.9 – 12.8) 0.107
Family member died of Liver disease
Yes 7(10.8) 361 (10.4)
No 58 (89.2) 3107 (89.6) 1.0 (0.5 – 2.3) 0.925
Diagnosis in Family member
HCV 1 (14.3) 12 (3.2)
HBV 1 (14.3) 36 (10) -
Jaundice 5 (71.4) 306 (84.8)
Liver disease 0 7 (2) 0.433
Sharing of various items with infected person
Yes 4 (57.1) 110 (31)
No 3 (42.9) 244 (69) 3.0 (0.7 – 13.4) 0.147
Previous Immunization
Vaccinated 54 (83) 3001(86.5)
Non-Vaccinated 11 (7) 467 (13.5) 1.3 (0.7 – 2.5) 0.419
Place vaccinated
Private Sector 7 (10.8) 1030 (29.7) Reference
Govt. Sector 46 (70.7) 1974 (57) 3.4 (1.5 – 7.6)
None 12 (18.5) 464 (13.3) 3.8 (1.5 – 9.7) 0.022
Visit to Barber Shop
Yes 47 (72.3) 2814 (81.1)
No 18 (27.7) 654 (18.9) 0.6 (0.4 – 1.1) 0.072
Received cuts at Barber Shop
Yes 11 (23.4) 686 (24.4)
No 36 (76.6) 2128 (75.6) 0.9 (0.5 – 1.9) 0.877
Child's ear/nose pierced
Yes 22 (33.8) 1293 (37.3)Page 4 of 10
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cant distribution in various ethnic groups.
Occupation of parents
27 (42%) of the HBsAg and 39 (71%) of the anti-HCV
positives father were employed as daily wage earners
while 60 (92%) of the HBsAg and 52 (94%) of anti-HCV
mothers were housewives.
Prior knowledge regarding Hepatitis B and C
60 (92%) HBsAg positive patients parents have not heard
of Hepatitis B (p = 0.830). 51 (93%) anti-HCV positive
patients parents have not heard of Hepatitis C virus (p =
0.815).
Risk factors
Therapeutic injections
45 (69.2%) children with HBsAg received therapeutic
injection as compared to 1766 (50.9%) HBsAg negative p
= 0.003 (Table 1). 28 (50.9%) with anti-HCV received
therapeutic injections as compared to anti-HCV negative
1783 (51.3%) p = 0.958 (Table 2). 44 (67.7%) HBsAg
positive received therapeutic injection with a new syringe
and needle as compared to 1694 (48.8%) HBsAg negative
p = 0.003 (Table 1). 28 (50.9 %) anti-HCV claimed to be
given by a new plastic syringe and needle every time as
compared to anti-HCV negative 1710 (49.2%) with [OR =
1.10; CI: 0.6–1.8 p = 0.798] (Table 2). There was an
increase in the number of HBsAg positive with an increase
in the number of therapeutic injections p = 0.140 (Table
1) however, no such relationship was demonstrated with
anti-HCV p = 0.427 (Table 2).
Previous immunization
54 (83%) HBsAg positive received vaccination while
3001(86.5%) did not (Table 1). Of those vaccinated 46
(70.7 %) received vaccination in the government health-
care facilities while only 7 (10.8%) in the private sector
[OR = 3.4; CI: 1.5–7.6 p = 0.02] (Table 1). 47 (85.5 %)
anti-HCV positive received vaccination while 8 (14.5 %)
did not. Of those vaccinated 33 (60%) received vaccina-
tion in the government healthcare facilities while only 14
(25.5%) in the private sector p = 0.93 (Table 2). Children
with previous vaccination in the government sector were
significantly positive for HBsAg 46 (70.7%) with [OR =
3.4; CI: 1.5–7.6 p = 0.02] (Table 1). However, this was not
so for anti-HCV (Table 2). There was no history of a child
No 43 (66.2) 2175 (62.7) 0.9 (0.5 – 1.4) 0.570
Dental treatment
Yes 0 107 (3)
No 65 (100) 3361 (97) - 0.150
Father education status
Educated 34 (52.3) 2300 (66.3)
Non-Educated 31 (47.7) 1168 (33.7) 1.8 (1.1 – 2.9) 0.018
Mother education status
Educated 25 (38.5) 1964 (56.6)
Non-Educated 40 (61.5) 1504 (43.4) 2.1 (1.3 – 3.5) 0.003
Ethnic Origin
Sindhi 1 (1.5) 86 (2.5) Reference
Balochi 12 (18.5) 133 (3.9) 7.8 (1.0 – 60.8)
Punjabi 10 (15.4) 996 (28.8) 0.9 (0.1 – 6.8) < 0.001
Pathan 4 (6.2) 179 (5) 1.9 (0.2 – 17.5)
Mohajirs 19 (29.2) 1796 (51.8) 0.9 (0.1 – 6.9)
Others 19 (29.2) 278 (8) 5.3 (0.7 – 40.1)
Age Group (years)
≤ 5 years 17 (26.2) 915 (26.4) Reference
6 – 9 years 14 (21.5) 931 (26.8) 0.8 (0.4 – 1.7)
10 – 13 years 16 (24.6) 934 (27) 0.9 (0.5 – 1.8)
> 13 years 18 (27.7) 688 (19.8) 1.4 (0.7 – 2.8) 0.428
Gender
Boys 38 (58.5) 1788 (51.6)
Girls 27 (41.5) 1680 (48.4) 1.3 (0.8 – 2.2) 0.270
Table 1: Demographic features and risk factors associated with seroprevalence of Hepatitis B in children (Continued)Page 5 of 10
(page number not for citation purposes)
BMC Infectious Diseases 2006, 6:101 http://www.biomedcentral.com/1471-2334/6/101Table 2: Demographic features and risk factors associated with seroprevalence of anti-Hepatitis C in children
Anti-Hepatitis C antibody
Risk Factor Positive n (%) Negative n (%) Odds Ratio (OR) 95% 
confidence interval (CI)
P value
Therapeutic Injections
Yes 28 (50.9) 1783 (51.3)
No 27 (49.1) 1695 (48.7) 0.9 (0.6 – 1.6) 0.958
Use of new needle & 
and syringe
Yes 28 (50.9) 1710 (49.2)
No 27 (49.1) 1768 (50.8) 1.0 (0.6 – 1.8) 0.798
No: of Injections in the 
last year
<2 injections 7(38.9) 368 (27.7) Reference
2–5 injections 4 (22.2) 471 (35.5) 0.4 (0.1 – 1.5)
>5 injections 7 (38.9) 489 (36.8) 0.8 (0.3 – 2.2) 0.427
Received Blood 
Transfusion
Yes 2 (3.7) 50 (1.4)
No 53 (96.3) 3428 (98.6) 2.6 (0.6 – 10.9) 0.179
Hospitalized
Yes 12 (21.8) 594 (17)
No 43 (78.2) 2884(83) 1.4 (0.7 – 2.6) 0.355
Family member died of 
Liver disease
Yes 8(14.5) 360 (10.3)
No 47 (85.5) 3118 (89.7) 1.5 (0.7 – 3.1) 0.312
Diagnosis in Family 
member
HCV 1 (12.5) 12 (3.4)
HBV 0 37 (10.5) -
Jaundice 7(87.5) 304 (86.1) 0.380
Previous Immunization
Vaccinated 47 (85.5) 3008 (86.5)
Non-Vaccinated 8 (14.5) 470 (13.5) 0.9 (0.4 – 2.0) 0.842
Place vaccinated
Private Sector 14 (25.5) 1023 (29.4) Reference
Govt. Sector 33 (60) 1987 (57.1) 1.2 (0.6 – 2.3)
None 8 (14.5) 469(13.5) 1.2 (0.5 – 3.0) 0.930
Visit to Barber Shop
Yes 45 (81.8) 2816 (81)
No 10 (18.2) 662 (19) 1.1 (0.5 – 2.1) 0.873
Received cuts at Barber 
Shop
Yes 7 (15.6) 690 (24.5)
No 38 (84.4) 2126 (75.5) 0.6 (0.3 – 1.3) 0.165
Child's ear/nose pierced
Yes 19 (34.6) 1296 (37.2)Page 6 of 10
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dentally by a used syringe and needle.
Visit to the Barber in those with positive serology
47 (72.3%) children with HBsAg p = 0.07 (Table 1) and
45 (81.8%) with anti-HCV p = 0.873 visited a barber for a
haircut (Table 2). 11 (23.4%) children with HBsAg p = 0.8
(Table 1) and 7 (15.6%) with anti-HCV p = 0.6 received
accidental cuts at the barber for a haircut (Table 2).
Piercing of nose and ears in those with positive serology
22 (33.8%) HBsAg positive p = 0.570 and 19 (34.6%)
anti-HCV positive p = 0.679 had piercing of nose or ears
(Table 1, 2).
Dental treatment
Previous dental treatment did not feature in HBsAg posi-
tive while 1 (0.9 %) with anti-HCV positive received it
(Table 2).
Tattooing
Tattooing was not practiced by the positive patients and
there was also no history of intravenous or other form of
drug addiction.
Discussion and conclusion
Pakistan lies between middle to low income countries
with over one-twelfth of labor force is unemployed, over
one third of the population subsists in poverty and over
half the population is illiterate, with parts of the country
being worse than what the national average indicates [20].
In 2001–2002 Pakistan received a grant from the Global
Alliance for Vaccines and Immunization (GAVI) that has
enabled the introduction of Hepatitis B vaccination in
routine Expanded Program on Immunization (EPI) [21].
Vaccination for HBV as part of EPI was launched in a
nationwide vaccination campaign in 2004 [22]. Special
attention was given to children under 1 year of age and to
married women who might bear children.
The limitations of our study are that we did not check the
hepatitis B core antibody and liver function tests. It would
have increased the cost and limited the study to a compar-
atively smaller size. This has led us to assess the extent of
problem in our vulnerable population and it will help our
health policy maker in future planning. In our study, the
prevalence of HBsAg was 1.8 percent and anti-HCV 1.6
percent in children with a mean age of 10 years and 9
years, respectively. These children have received primary
No 36 (65.4) 2182 (62.8) 0.9 (0.5 – 1.6) 0.679
Dental treatment
Yes 1 (1.9) 106 (3)
No 54 (98.1) 3372 (97) 0.6 (0.1 – 4.3) 0.598
Father education status
Educated 36 (65.5) 2298 (66)
Non-Educated 19 (34.5) 1180 (34) 1.0 (0.6 – 1.8) 0.924
Mother education 
status
Educated 24 (43.7) 1965 (56.5)
Non-Educated 31 (56.3) 1513 (43.5) 1.7 (0.9 – 2.9) 0.056
Ethnic Origin
Sindhi 1 (1.8) 86 (2.5) Reference
Balochi 3 (5.5) 142 (4) 1.8 (0.2 – 17.7)
Punjabi 16 (29) 990 (28.5) 1.4 (0.2 – 10.6)
Pathan 4 (7.3) 179 (5.1) 1.9 (0.2 – 17.5) 0.568
Muhajirs 23 (41.8) 1792 (51.5) 1.1 (0.1 – 8.3)
Others 8 (14.6) 289 (8.4) 2.4 (0.3 – 19.3)
Age Group (years)
<= 5 13 (23.5) 919 (26.4) Reference
6–9 14 (25.5) 931 (26.8) 1.1 (0.5 – 2.3)
10–13 14 (25.5) 936 (27) 1.1 (0.5 – 2.3)
> 13 14 (25.5) 692 (19.8) 1.4 (0.7 – 3.1) 0.783
Gender
Boys 32 (58.2) 1794 (51.6)
Girls 23 (41.8) 1684 (48.4) 0.7 (0.4–1.3) 0.331
Table 2: Demographic features and risk factors associated with seroprevalence of anti-Hepatitis C in children (Continued)Page 7 of 10
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educational status of parents of HBsAg positive children
was significantly low only on univariable analysis (Table
1, 3). Both children and their parents had a poor knowl-
edge of HBV and HCV related diseases. A number of HBV
positive children received therapeutic injections from
local general practitioners not using a new syringe. How-
ever, children receiving therapeutic injections with new
needles and syringes also demonstrated a high prevalence
of HBV. This could be explained by unlawful practices in
the country of used syringes being washed and packaged
for re-sale [23]. This highlights the inadequate system of
medical waste disposal in the community. To maximize
their profit medical practitioners in the private sector rou-
tinely reuses syringes and only changes the needle when it
gets blunt. It is estimated that about half of all injections
administered in Pakistan involve reused syringes [23].
Also, use of multiple-dose vials is considered an impor-
tant source of patient-patient transmission of hepatitis B
and C. In our study, number of cases with HBV increased
with the number of injections received. However, this was
not observed in children with positive HCV. In an earlier
study, non-sterile syringes and needles were also the
source of HCV and HBV infections in a peri urban com-
munity of Karachi [24]. Patients who received more injec-
tions were more likely to be infected with HCV [24]. Also,
non-sterile syringes and needles that had been used earlier
in the day on other patients were used for 94% of the
observed injections. Previous hospitalization, dental
treatment, blood transfusion, visiting and receiving cuts at
Barber shops, piercing of ears and nose, presence of
HBsAg carriers and/or HCV chronically infected subjects
among family members, death of a family member due to
liver disease did not feature as contributing risk factors in
our study. There was no history of needle stick injuries
and practice of tattooing. Piercing of nose and ears, use of
inadequately sterilized instruments, with clients receiving
accidental cuts in various practices including in barber
shops were reported. Previous vaccination was largely
received at the public health-care facilities. A nationwide
survey by the ministry of health in 2002 revealed that as
many as 72% therapeutic injections and 50% immuniza-
tion injections in public health-care facilities were unsafe
and potentially dangerous [23]. The irrational use of
drugs is a major problem. When prescriptions from 60
public and 48 private health facilities were compared over
48% of GP prescriptions had at least one injectable drug
compared with 22.0% by public providers (p < 0.0001)
[25].
The implication of this study is that seropositivity was
comparatively higher for HBsAg in children than for anti-
HCV. However, the difference between their prevalence
was not statistically significant. This suggests that mother/
child transmission of HBV may have also followed. The
possible contribution to prevalence of HBsAg of a birth to
an HBV carrier mother cannot be ruled out. However,
HBsAg and anti-HCV status of mothers was not estab-
lished in this study. It is difficult to estimate what percent
of these viral infections could be attributed to each of the
risk factors in our study as numbers of positive cases were
small and in HCV positive cases none achieved even uni-
variable significant level. In a previous study, eight (3.3%)
of 245 mothers tested positive for HBsAg, all babies born
to mothers with HBV infection were negative for this
marker [26,27]. It concluded that vertical transmission in
the early perinatal period is the least. In comparison peri-
natal transmission of HCV occurs at the time of birth in
Table 3: Independent risk factors associated with seroprevalence of Hepatitis B in children identified in multiple logistic regression
Risk Factor Adjusted odds Ratio (AOR) 95% confidence interval (CI) P value
Use of new needle & and 
syringe
No Reference
Yes 1.9 (1.1 – 3.3) 0.033
Place vaccinated
Private Sector Reference
Govt. Sector 2.4 (1.1 – 5.2) 0.030
Father education status
Educated Reference
Non-Educated 1.4 (0.7 – 2.7) 0.333
Mother education status
Educated Reference
Non-Educated 1.4 (0.6 – 2.7) 0.361Page 8 of 10
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women almost exclusively from mothers who are HCV-
RNA positive [28,29]. General sero-prevalence of anti-
HCV and HBsAg in healthy adult male population from
the northern Pakistan was 5 percent for anti-HCV and 2.5
percent for HBsAg [30]. This reflects that the population at
large is exposed to the same risk factors. Low educational
level and/or low socio-economic status has also been
associated with the prevalence of a number of infectious
diseases. This is in keeping with Mujeeb et al who
described areas of higher prevalence of Hepatitis C located
in specific districts and a trend of higher prevalence in less
affluent urban areas for the city of Karachi [31]. In our
study the odd of a positive test for HBsAg was 2.2 in those
receiving therapeutic injection as compared to those who
did not. It is imperative that for eradication of HBV infec-
tion universal vaccination of all newborns is carried out
together with education of the public to limit injections to
those which are safe and clinically indicated.
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